Angiotensin II Antagonist in Severe Sepsis

Summary

The investigators propose a clinical study of irbersartan for the early treatment of severe sepsis patients with elevated predicted risk of death between. This study will evaluate whether early administration of the the angiotensin receptor blocker irbersartan provides significant reduction of 28 days mortality and multi organ failure incidence to patients with severe sepsis.

Timeline

Start

2014-01

Primary completion

2017-01

Completion

2017-01

Drugs

Indications